Monday, November 18, 4:15pm<\/p>\n\n\n\n
![\"\"](\"https:\/\/eas.org\/2024\/wp-content\/uploads\/2024\/07\/Keynote-Photo-Ronald-P.-2024-scaled.jpg\")
<\/a><\/figure>\n\n\n\nRole of Quality and Analytical in Supporting Industry Growth in LMICs<\/em> Ronald T. Piervincenzi, Ph.D., began his tenure as Chief Executive Officer of the United States Pharmacopeia in February 2014. Dr. Piervincenzi provides strategic leadership to USP\u2019s global staff of over 1,300 across regions including North America, Latin America, Southeast Asia, Middle East and Africa, Europe, and global public health field offices across nine countries. His transformative vision has launched key USP initiatives in bringing quality across the healthcare spectrum, upholding USP\u2019s reputation as a quality leader since its founding in 1820. Under his leadership, USP has modernized its operations and launched innovative new science, including in the areas of digital medicine, cutting-edge manufacturing technologies and advanced biologics. Recently, USP has begun building a robust \u201ccapability building\u201d services suite of offerings including quality manufacturing consulting, donor-funded work, and education.<\/p>\n\n\n\n Dr. Piervincenzi brings more than 25 years of industry experience across pharmaceutical sciences, research and business strategy. Before joining USP, Dr. Piervincenzi served as Vice President of Development Sciences with Biogen and was a partner and leader in McKinsey & Company’s global pharmaceutical and medical products practice for over 12 years. Dr. Piervincenzi earned his M.S. and Ph.D. from Duke University in Biomedical Engineering, with research focused on protein engineering. He is the proud co-founder and chairman of the board for MENTOR Newark.<\/p>\n\n\n\n <\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" We are excited to announce Dr. Ronald Piervincenzi, USP, will be giving a Keynote lecture! We invite all registered attendees and exhibitors to […]<\/p>\n","protected":false},"author":2,"featured_media":11685,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[28,1],"tags":[],"class_list":["post-7861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-featured","category-info"],"_links":{"self":[{"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/posts\/7861"}],"collection":[{"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/comments?post=7861"}],"version-history":[{"count":4,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/posts\/7861\/revisions"}],"predecessor-version":[{"id":11686,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/posts\/7861\/revisions\/11686"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/media\/11685"}],"wp:attachment":[{"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/media?parent=7861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/categories?post=7861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eas.org\/2024\/wp-json\/wp\/v2\/tags?post=7861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Dr. Ronald T. Piervincenzi<\/strong>
CEO | Member, Board of Trustees (ex officio) | Officer, USP Convention
United States Pharmacopeia
<\/p>\n\n\n\n